Canary Wharf Group (CWG) has sealed a series of deals with life sciences focused start-up and scale-up businesses at its co-working office hub Level39 at One Canada Square.
The hub, which CWG launched 10 years ago, is now home to more than 180 businesses, with the latest additions including biotech company TC BioPharm, ethical AI company Neural Rays and Sanius Health, a health tech company dedicated to improving rare diseases treatment.
The Cancer Awareness Trust is also using Level39 as a base to carry out its pioneering work, and it has been joined by L Base, a biotech company specialising in innovative R&D of cancer drugs. In addition, digital health company Congenica has also recently extended its long-term commitment to Level39.
CWG is on track to launch the new life sciences innovation centre at 20 Water Street in June this year as part of the developer’s joint venture with Kadans to build a life sciences cluster at Canary Wharf, which includes the creation of a new 823,000 sq ft commercial lab building at North Quay, due to open in 2026.
Richard Archer, managing director of offices at Canary Wharf Group, said: “Our strategy is to make Canary Wharf one of Europe’s leading centres for life sciences, and establishing an ecosystem of inter-connected companies is a key element to achieving that goal. Having welcomed a raft of new members at Level39, we are building real momentum in growing this cluster whilst working seamlessly in tandem with the development of the new vertical life sciences campus at North Quay.”
James Sheppard, managing director of Kadans Science Partner, added: “The rapid emergence of such a vibrant community of life sciences companies at Level39 is a sure sign of the growing recognition of Canary Wharf’s potential as the home for a major UK and European ecosystem of life sciences, providing a best in class space for the broad and diverse range of companies operating in the sector.”
